It was shown that the topical ophthalmic administration of MSC exosomes containing miR-204 (which directly targets interleukin-6 receptor to suppress the activation of the proinflammatory IL-6/IL-6R/Stat3 pathway) improved DED related to refractory GVHD by providing substantial relief in symptomatology, improving corneal epithelialization and increasing tear secretion [194]. The gene discussed is IL6R; the disease is graft versus host disease.